Context Therapeutics Inc. (CNTX)
Pre-market:
| Previous close | 2.0600 |
| Open | 2.0100 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1300 |
| Day's range | 1.9300 - 2.0700 |
| 52-week range | 1.2700 - 10.8700 |
| Volume | |
| Avg. volume | 376,935 |
| Market cap | 31.932M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.9300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- GlobeNewswire
Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results
Abstract on results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary accepted for oral presentation at the 2022 ASCO Annual Meeting Preclinical data presented at AACR Annual Meeting showcased potential of ONA-XR and CLDN6xCD3 bispecific development program PHILADELPHIA, May 11, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treat
- GlobeNewswire
Context Therapeutics® Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting
Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates monotherapy clinical activity in advanced granulosa cell tumor of the ovary Trial advanced to second stage to evaluate combination of ONA-XR with oral antiestrogen PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced
